List of adverse effects of pazopanib
This is a list of adverse effects of the anti-cancer drug pazopanib, sorted by frequency of occurrence.[1][2][3][4][5]
Very common
Very common (>10% incidence) adverse effects include:
- Reduced appetite
- Headache
- Taste changes
- High blood pressure[Note 1]
- Diarrhoea
- Abdominal pain
- Nausea
- Vomiting
- Hair colour change
- Hand-foot syndrome
- Hair loss
- Rash
- Fatigue
- Increased alanine aminotransferase
- Increased aspartate aminotransferase
- Tumour pain‡
- Myelosuppression‡[Note 2]
- Stomatitis‡
- Exfoliative rash‡
- Skin hyperpigmentation‡
- Weight loss‡
Common
Common (1–10% incidence) adverse effects include:
- Tumour pain†
- Myelosuppression†[Note 3]
- Underactive thyroid
- Dehydration
- Low level of phosphate in the blood
- Dizziness
- Lethargy
- Paraesthesia
- Peripheral sensory neuropathy
- Blurred vision
- Hot flush
- Venous thromboembolic event
- Flushing
- Nose bleed
- Voice anomalies
- Shortness of breath
- Coughing up blood
- Stomatitis
- Indigestion
- Flatulence
- Abdominal distension
- Dry mouth
- Mouth ulceration
- Hyperbilirubinaemia
- Abnormal liver function
- Hepatotoxicity
- Skin hypopigmentation
- Dry skin
- Itchiness
- Erythema
- Skin depigmentation
- Hyperhidrosis
- Joint pain
- Muscle aches
- Muscle spasms
- Protein in the urine
- Mucosal inflammation
- Weakness
- Oedema
- Chest pain
- Weight loss†
- Increased blood creatinine
- Lipase increased
- Decreased white blood cell count
- Blood TSH decreased
- Amylase increased
- Gamma-glutamyltransferase increased
- Increased blood pressure
- Increased blood urea
- Abnormal liver function test
- Gingival infection‡
- Dizziness
- Insomnia
- Peripheral sensory neuropathy
- Heart dysfunction
- Blurred vision
- Low heart rate
- Left ventricular dysfunction
- Bleeding (including haemorrhage)
- High blood sugar
- Low blood sugar
Uncommon
Uncommon (0.1–1% incidence) adverse effects include:
- Torsades de pointes
- Heart failure
- Liver failure
- GI perforation (may be fatal)
- Fistula formation
Rare
Rare (<0.1% incidence) adverse effects include:
- Reversible posterior leucoencephalopathy syndrome
Notes
† Denotes side effects seen at the above frequency only in clinical trials performed in people with renal cell carcinoma.
‡ Denotes side effects seen at the above frequency only in clinical trials done in people with soft tissue sarcomas.
- Usually occurs within the first 18 weeks of treatment. 39% of cases develop within the first 9 days of treatment.
- This includes leucopenia, thrombocytopenia and neutropenia.
- This includes leucopenia, lymphopenia, thrombocytopenia and neutropenia.
References
- "Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 27 January 2014.
- "VOTRIENT (pazopanib hydrochloride) tablet, film coated" (PDF). DailyMed. GlaxoSmithKline LLC. November 2013. Retrieved 27 January 2014.
- "Votrient : EPAR - Product Information" (PDF). European Medicines Agency. Glaxo Group Ltd. 23 January 2014. Retrieved 27 January 2014.
- "Votrient 200 mg and 400 mg film coated tablets - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. GlaxoSmithKline UK. 20 December 2013. Retrieved 27 January 2014.
- "PRODUCT INFORMATION VOTRIENT® TABLETS" (PDF). TGA eBusiness Services. GlaxoSmithKline Australia Pty Ltd. 25 March 2013. Retrieved 27 January 2014.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.